FDA Approves ERIBULIN MESYLATE — Meitheal Pharmaceuticals Inc.
On October 19, 2026, Meitheal Pharmaceuticals Inc. received FDA approval for the Intravenous formulation of Eribulin Mesylate under ANDA 218930, a decision likely to stimulate market competition and optimize treatment costs within the chemotherapy oncology sector by broadening supply options for the drug.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed